Related Experiment Videos
Effects of recombinant human erythropoietin in infants with very low birth weights
1Department of Obstetrics and Gynaecology, Istanbul Faculty of Medicine, Istanbul University, Turkey.
Insights
Recombinant human erythropoietin (r-HuEpo) treatment in premature infants reduced the need for erythrocyte transfusions. This therapy effectively increased red blood cell production without adverse effects, offering a promising alternative.
Area of Science:
- Neonatal Medicine
- Hematology
- Pharmacology
Background:
- Anemia of prematurity is common in infants born before 32 weeks gestation.
- Inadequate erythropoietin production is a key factor contributing to this condition.
- Erythrocyte transfusions are a common but potentially risky treatment.
Purpose of the Study:
- To evaluate the efficacy of recombinant human erythropoietin (r-HuEpo) in treating or preventing anemia of prematurity.
- To determine if r-HuEpo can reduce the requirement for erythrocyte transfusions in premature infants.
- To assess the safety profile of r-HuEpo in this vulnerable population.
Main Methods:
- A randomized controlled trial involving premature infants (birth weight <= 1250 g, gestational age <= 32 weeks).
- Participants received either subcutaneous r-HuEpo (200 U) or placebo three times weekly for 4 weeks, alongside iron supplementation.
- Treatment commenced in the third week of life.
Main Results:
- Reticulocyte counts were significantly elevated in the r-HuEpo group, indicating increased red blood cell production.
- Infants treated with r-HuEpo required fewer erythrocyte transfusions compared to the placebo group.
- No toxic effects were attributed to the administration of r-HuEpo.
Conclusions:
- Subcutaneous administration of r-HuEpo is effective in treating anemia of prematurity.
- r-HuEpo treatment significantly reduces the need for erythrocyte transfusions in very low birth weight infants.
- r-HuEpo represents a safe and viable alternative to transfusion therapy for premature neonates.
Abstract:
Anaemia of prematurity, a postnatal fall in haemoglobin concentration and haematocrit, is particularly common in those born at less than 32 weeks of gestation. Experimental and clinical data implicate inadequate erythropoietin production as an important reason. In this study recombinant human erythropoietin (r-HuEpo) was used in an attempt to treat or prevent this anaemia and thereby provide an alternative to erythrocyte transfusions. Premature infants (birth weight < or = 1250 g and gestational age < or = 32 weeks), who were likely to need transfusions, were randomly assigned to receive 4 weeks of treatment with either subcutaneously administered r-HuEpo (200 U; n = 12) or placebo (n = 12), three times weekly. All patients had oral supplements of elemental iron at a dose of 3 mg/kg/day. Treatment was started in the third week of life. Reticulocyte counts were significantly raised (P < 0.05) in the group treated with r-HuEpo at the end of treatment. The neonates in the group treated with r-HuEpo needed fewer erythrocyte transfusions than those in the placebo group during treatment. There were no toxic effects attributable to r-HuEpo. The results indicate that treatment of infants with very low birth weights with r-HuEpo will reduce their need for erythrocyte transfusions.